# Pembrolizumab In Central Nervous System Metastases

> **NCT02886585** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 101 (estimated)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** MRI
- **RADIATION:** PET/CT
- **PROCEDURE:** Stereotactic Radiosurgery

## Key facts

- **NCT ID:** NCT02886585
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02886585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02886585, "Pembrolizumab In Central Nervous System Metastases". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02886585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*